BridgeBio Pharma
Yahoo Finance • 14 hours ago
Alnylam drops as AstraZeneca posts full trial results for failed heart drug
[Alnylam Pharmaceuticals, Inc.] hapabapa/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed w... Full story
Yahoo Finance • 3 days ago
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
BridgeBio Pharma BBIO entered the second half of 2026 with Attruby doing most of the commercial heavy lifting. Second-quarter revenues rose 120% year over year and topped the Zacks Consensus Estimate, but the company still posted a wider-t... Full story
Yahoo Finance • 3 days ago
Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?
BridgeBio Pharma BBIO is entering a pivotal commercial stretch. Attruby is scaling quickly, while three late-stage candidates could widen the company's revenue base over the next year. The trade-off is a demanding valuation alongside cont... Full story
Yahoo Finance • 3 days ago
Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue
BridgeBio Pharma BBIO shares have gained 24% in the past three months, far ahead of the S&P 500's 0.7% rise over the same period. The move leaves investors weighing whether improving commercial and pipeline momentum can support further gai... Full story
Yahoo Finance • 18 days ago
BridgeBio outlines three launches with first PDUFA set for November 27, 2026 and RECLAIM-HP readout in next 18 months
Earnings Call Insights: BridgeBio Pharma (BBIO) Q2 2026 MANAGEMENT VIEW * CEO Neil Kumar framed Q2 as a turning point, saying, "it feels like we're at T=0 in BridgeBio's next chapter," and tied near-term value creation to Attruby’s nex... Full story
Yahoo Finance • 2 months ago
Panic grips Ionis Pharmaceuticals investors amid bad news spree
A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua fai... Full story
Yahoo Finance • 2 months ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7... Full story
Yahoo Finance • 2 months ago
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story
Yahoo Finance • 2 months ago
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story
Yahoo Finance • 2 months ago
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS... Full story
Yahoo Finance • 2 months ago
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions... Full story
Yahoo Finance • 3 months ago
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
Quick Read: The AI/Data Center chip rally continued to drive the market higher on Tuesday. Now, legacy tech old-school tech giants are joining the rally, as Hewlett Packard Enterprises had its biggest day ever. Despite the giddy, never-en... Full story
Yahoo Finance • 3 months ago
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Yum! Brands(YU... Full story
Yahoo Finance • 3 months ago
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk
Quick Read BridgeBio Pharma (BBIO) received a Neutral initiation from Citi, signaling caution on BridgeBio despite 22 buy ratings on the stock and Q1 2026 Attruby revenue of $180.6M, up 399% year over year. Citi’s cautious stance reflects... Full story
Yahoo Finance • 3 months ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story
Yahoo Finance • 4 months ago
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and key secondary effi... Full story
Yahoo Finance • 4 months ago
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM -Acoramidis further dem... Full story
Yahoo Finance • 4 months ago
A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline Expectations
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BridgeBio Pharma stock snapshot after recent trading performance... Full story
Yahoo Finance • 4 months ago
BridgeBio to Participate in May and June Investor Conferences
PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of... Full story
Yahoo Finance • 4 months ago
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - By Month 1, numeric... Full story